Levodopa News and Research

RSS

NeuroDerm signs definitive investment agreements for $16 million financing round

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has signed definitive investment agreements for a $16 million financing round led by certain of its existing investors with the participation of new investors, including The Elias Group.

21 Aug 2014

Study: Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Levodopa is the preferred treatment for Parkinson's disease in the clinic. However, long-term use of levodopa may lead to various motor complications, among which levodopa-induced dyskinesia is the most common, severely affecting patients' quality of life.

5 Aug 2014

Sleep problems in PD patients can worsen in later stages of disease

Up to 70% of Parkinson's disease (PD) patients experience sleep problems that negatively impact their quality of life.

11 Jul 2014

PD MED trial: Levodopa drug better for long-term treatment of newly diagnosed PD

For long-term treatment of newly diagnosed Parkinson’s disease (PD), the old drug levodopa provides better mobility and a higher quality of life than the two main alternatives, dopamine agonists (DA) and monoamine oxidase type B inhibitors (MAOBI), according to the largest-ever trial of PD treatment (PD MED), published in The Lancet.

13 Jun 2014

Study heterogeneity hinders mortality predictions in Parkinson’s disease

Poor study quality and heterogeneity in study methods and patients make it difficult to determine the impact Parkinson’s disease has on mortality, UK researchers report.

6 Jun 2014

Dopamine transporter availability predicts ICDs

Reduced striatal dopamine transporter availability is already present in patients with Parkinson’s disease who go on to develop impulse control disorders, a study shows.

5 Jun 2014

Newron Pharmaceuticals submits safinamide NDA to FDA

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area with a long experience in respiratory disease therapies, woman care and primary care, announce that the New Drug Application (NDA) for safinamide was submitted today to the US Food and Drug Administration (FDA).

30 May 2014

Presynaptic dopaminergic lesion predicts drug-induced dyskinesia

Research suggests that the extent of presynaptic dopaminergic denervation before starting therapy may predict which patients with Parkinson’s disease will later develop levodopa-induced dyskinesia.

19 May 2014

Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

6 May 2014

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

A review by the American Academy of Neurology of available scientific research on the use of medical marijuana in brain diseases finds certain forms of medical marijuana can help treat some symptoms of multiple sclerosis (MS), but do not appear to be helpful in treating drug-induced (levodopa) movements in Parkinson's disease.

29 Apr 2014

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing and commercializing transformative therapeutics using its proprietary ARCUSTM technology, today announced positive results from a Phase 2b clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

29 Apr 2014

New insights into possible common links between neurodegenerative diseases

The pattern of brain alterations may be similar in several different neurodegenerative diseases, which opens the door to alternative therapeutic strategies to tackle these diseases

21 Apr 2014

Impax resubmits NDA for RYTARY providing updated safety and stability information

Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration (FDA).

11 Apr 2014

New discovery opens door to development of new treatments that stop progression of Parkinson's disease

A research led by the Research Institute Vall d'Hebron (VHIR), in which the University of Valencia participated, has shown that pathological forms of the α-synuclein protein present in deceased patients with Parkinson's disease are able to initiate and spread in mice and primates the neurodegenerative process that typifies this disease.

10 Apr 2014

Parkinson disease patients with higher CSF experience faster cognitive decline

Counterintuitive Findings Offer New Insights into Parkinson Disease Pathology, According to New Research Published in The American Journal of Pathology

12 Mar 2014

NeuroDerm enrolls patients in second ND0612 Phase II clinical trial for treatment of Parkinson's disease

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease.

11 Mar 2014

Circadian dysfunction blamed for sleepiness in PD patients

Patients with Parkinson’s disease, particularly those with excessive daytime sleepiness, have reduced melatonin levels and amplitude of the melatonin circadian rhythm, research shows.

6 Mar 2014

Deep-brain stimulation boosts PD patients’ driving performance

Deep-brain stimulation reduces errors among patients with Parkinson’s disease undergoing a driving simulator test, a study shows.

14 Jan 2014

Slower decline for patients with PARKIN-associated PD

Cognitive and motor decline may be slower in patients with early-onset Parkinson’s disease if they have PARKIN mutations, suggests an analysis of the Consortium on Risk for Early-Onset PD study.

8 Jan 2014

Deep brain stimulation may have beneficial effect on driving ability for Parkinson's disease patients

Deep brain stimulation may have a beneficial effect on driving ability for people with Parkinson's disease, according to a new study published in the December 18, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. Deep brain stimulation uses a surgical implant similar to a pacemaker to send electrical impulses to the brain.

19 Dec 2013